Ekso Bionics Holds Exciting Third Quarter Results
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a leader in innovative exoskeleton technology, recently disclosed its financial results for the third quarter of 2024, marking significant milestones for the company and the exoskeleton industry.
Key Financial Highlights
The company reported an impressive revenue of $4.1 million for the quarter ending September 30, 2024, indicating resilience despite previous challenges. In total, Ekso Bionics successfully sold 33 EksoHealth devices during this quarter, demonstrating a strong demand for their offerings.
Achievements in Reimbursement
A significant highlight during this quarter was the announcement regarding the initial reimbursement approval from the Centers for Medicare & Medicaid Services (CMS) for the Ekso Indego Personal device. This breakthrough is a huge step forward, providing spinal cord injury patients with easier access to this transformative mobility technology.
Financial Metrics Revealed
Despite revenue slightly decreasing from $4.6 million in the previous year, the gross profit for Q3 2024 stood at $2.2 million, showing a gross margin of 53.5%, a slight improvement from 53.3% the previous year. This margin increase was propelled by strategic cost-saving measures in the supply chain and reduced service costs, even as there was a noticeable decline in lower-margin sales through distribution channels.
Expense Management
In terms of operating expenses, the sales and marketing costs have decreased to $1.8 million, down from $2.1 million a year earlier. This reduction was attributed to lower headcount and reduced discretionary expenses. Similarly, research and development expenses dropped by 33% from $1.2 million to $0.8 million, highlighting the company’s commitment to managing costs effectively while still pushing forward in innovation.
Long-term Outlook and Business Focus
Looking at the overall picture, net loss applicable to common stockholders narrowed to $2.1 million, translating to $0.10 per basic and diluted share, which is a substantial improvement from a net loss of $3.4 million, or $0.24 per share, in the previous year. For the nine months ending September 30, revenue totaled $12.8 million, a slight dip from $13.4 million last year but indicative of a steady performance in a cyclical market.
Future Steps
CEO Scott Davis emphasized the company’s continued dedication to expanding access to EksoHealth devices in various care settings. He acknowledged ongoing collaborations with healthcare facilities, physicians, and durable medical equipment providers as pivotal to generating future sales. The focus will remain on normalizing procurement cycles in response to evolving market needs.
Positive Cash Flow Movements
On the financial health side, Ekso Bionics had approximately $8.3 million in cash as of September 30, 2024, representing a slight decrease from $8.6 million at the end of 2023. The company also concluded a public offering, raising about $5.0 million in net proceeds, reinforcing their liquidity position amidst operational demands.
Conference Call Discussion
Management hosted a conference call to discuss these results and recent developments, allowing investors a deeper insight into the company’s trajectory. For those unable to attend, the webinar will be archived on their website for further review.
About Ekso Bionics
Founded in 2005, Ekso Bionics is recognized for creating pioneering exoskeleton solutions that enhance mobility, strength, and endurance across multiple sectors including healthcare and industrial applications. Holding a leading stance in the industry, the company is devoted to continual innovation and the advancement of exoskeleton therapies.
Frequently Asked Questions
What are the recent revenue figures for Ekso Bionics?
Ekso Bionics reported $4.1 million in revenue for the third quarter of 2024.
What significant development occurred with CMS?
Ekso Bionics received initial CMS reimbursement for the Ekso Indego Personal, enhancing access for spinal cord injury patients.
How has the company managed expenses recently?
The company has cut costs in sales and marketing, and research and development, indicating a strong focus on expense management.
What is the net loss reported by Ekso Bionics?
The net loss applicable to common stockholders narrowed to $2.1 million for the quarter ending September 30, 2024.
Where can I find more information about Ekso Bionics?
Additional details about the company and its offerings can be found on the official Ekso Bionics website.
